68
Headline
Catheter Ablation Fails to Demonstrate Superior Quality-of-Life Improvement Over Sham Procedure in Atrial Fibrillation at 6 Months: The PVI-SHAM-AF Trial
1-Minute Summary
In the randomized, double-blind, multicenter PVI-SHAM-AF trial presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in The Lancet, catheter ablation for symptomatic atrial fibrillation (AF) did not achieve statistically significant superiority over a sham procedure for improving disease-specific quality of life at 6 months. While catheter ablation significantly reduced arrhythmia recurrence compared with sham intervention (21% vs 41%), both cohorts experienced substantial improvements in scores on the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire. These findings highlight a substantial placebo and non-specific care effect in interventional electrophysiology, demonstrating a divergence between objective rhythm control and patient-reported symptomatic improvement.
Why This Matters
Current clinical practice guidelines recommend catheter ablation primarily to relieve symptoms and enhance quality of life in patients with drug-refractory or symptomatic atrial fibrillation. However, because open-label trials cannot account for procedural placebo responses, patient expectation, or intensive clinical contact, the true magnitude of symptom relief attributable solely to pulmonary vein isolation has remained debated. Following conflicting results from earlier sham-controlled investigations, these findings prompt clinicians to differentiate between objective sinus rhythm restoration and perceived quality-of-life gains during patient counseling and shared decision-making.
Study at a Glance
| Feature | Details |
| Study type | Multicenter, randomized, double-blind, sham-controlled trial |
| Participants | 262 patients with symptomatic atrial fibrillation eligible for catheter ablation under ESC guidelines across 9 sites in Germany and Poland |
| Intervention | Catheter ablation (pulmonary vein isolation) with cardioversion if AF occurred intraprocedurally |
| Comparator | Sham procedure (conscious sedation, two femoral venous punctures, no transseptal puncture or left atrial mapping/ablation, with cardioversion if AF occurred) |
| Primary outcome | Change in the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire summary score from baseline to 6 months |
| Main finding | No statistically significant difference in AFEQT improvement between catheter ablation and sham (between-group difference: 2.6 points; 95% CI, 2.7 to 8.0; P = .36); catheter ablation reduced AF recurrence at 6 months (21% vs 41%; difference: 20.1 percentage points) |
| Follow-up | 6 months |
What the Researchers Found
The trial evaluated whether the clinical benefits of pulmonary vein isolation reflect the physiological consequences of left atrial lesion delivery or non-specific procedural effects. Lead investigator Rolf Wachter, MD, professor at the Clinic and Polyclinic for Cardiology at University Hospital Leipzig, explained the investigative premise:
โWe started with the question, what is the real effect of catheter ablation on quality of life? To do this, we did a randomized multicenter double-blind trial and we found out that … catheter ablation did not prove superiority to the sham procedure for improvement in the prespecified [Atrial Fibrillation Effect on the Quality of Life Questionnaire] summary score at 6 months.โ
Primary and Secondary Outcomes at 6 Months
| Outcome Measure | Catheter Ablation (n = 131) | Sham Procedure (n = 131) | Effect Size / Difference (95% CI) | P Value |
| Baseline AFEQT Score, mean | 61.3 | 59.2 | โ | โ |
| 6-Month AFEQT Score, mean | 81.1 | 74.9 | โ | โ |
| Change in AFEQT Score | +19.8 | +15.7 | Between-group difference: 2.6 (2.7 to 8.0) | .36 |
| Documented AF Recurrence at 6 Months | 21.0% | 41.0% | Difference: 20.1 percentage points (7.7 to 32.6) | Significant |
Both study groups experienced marked improvements in functional status and well-being. However, the incremental gain observed with active ablation failed to separate significantly from the sham intervention.
Contrasting these results with earlier evidence, Dr. Wachter remarked:
โWe were surprised. It probably shows that our sham was pretty good. Two years ago, there was a trial presented here, and they had a similar effect on AFEQT by catheter ablation, but not so much by the sham.โ
Clinical Significance
The trial reveals a distinct dissociation between electrophysiological rhythm restoration and patient-perceived symptomatic benefit. Although pulmonary vein isolation halved the absolute risk of arrhythmia recurrence at 6 months (21% vs 41%), the sham intervention generated a 15.7-point improvement in AFEQT scoreโwell above the accepted threshold for clinical relevance.
This pronounced sham response points to the strong therapeutic impact of structured peri-procedural surveillance, sedation, hospital admission, and post-procedural medical care.
Dr. Wachter summarized the implications:
โWe had a symptomatic improvement observed after ablation, but this cannot necessarily be attributed entirely to the ablation procedure, although other sham control trials have reported an incremental quality of life benefit. Clinical counseling should consider data from sham control trials along the broader evidence base. The main finding is that we have to distinguish objective rhythm control benefits from effects on patient-reported quality of life. As a more general remark, the impact of the technical procedure catheter ablation probably has been overestimated in previous research, and we have underestimated the impact of active human care on these patients. Future research is needed to identify the patients who obtain most symptomatic benefits from catheter ablation.โ
Limitations
- Follow-up Duration: Outcomes were assessed at 6 months; longer-term follow-up is necessary to evaluate whether sustained sinus rhythm yields widening quality-of-life divergence over multi-year intervals.
- Conflicting Prior Evidence: The findings contrast with the 2024 SHAM-PVI trial published in JAMA, in which ablation demonstrated significant quality-of-life superiority over sham, suggesting potential differences in patient populations, background antiarrhythmic drug use, or procedural protocols.
- Generalizability: The trial enrolled patients across 9 centers in Germany and Poland who met strict trial criteria; outcomes may vary across broader community cohorts or differing AF phenotypes (e.g., long-standing persistent AF vs paroxysmal AF).
What Doctors Should Know
- Re-evaluate Quality-of-Life Indications: When offering ablation solely to enhance subjective well-being, clinicians should exercise greater diagnostic caution. When asked whether the results alter candidate selection, Dr. Wachter noted:โIf quality of life is the one and only reason [to offer ablation], I think we should look closer than before.โ
- Recognize the Value of Active Medical Care: Reassurance, structured follow-up, and multidisciplinary lifestyle support contribute substantially to symptom abatement, independently of catheter manipulation.
- Ablation Remains Effective for Rhythm Maintenance: For patients in whom objective rhythm control, reduction of arrhythmia burden, or prevention of tachycardia-induced cardiomyopathy is the primary therapeutic target, catheter ablation remains effective and superior to sham.
Bottom Line
In symptomatic atrial fibrillation, catheter ablation significantly reduces objective arrhythmia recurrence compared with a sham procedure, but it does not confer superior quality-of-life improvements at 6 months due to a large and clinically meaningful sham response.
Original Research / Reference
Wachter R, et al. PVI-SHAM-AF: A randomized, multicenter, double-blind, sham-controlled trial of catheter ablation for atrial fibrillation. The Lancet. 2026. Presented at: European Society of Cardiology (ESC) Congress; August 28โ31, 2026; Munich, Germany.
